Clinical/scientific notes

Neurology

Volumn 79, Issue 20, 2012, Pages 2075-2077

  Von Geldern, Gloria ^a   Pardo, Carlos A ^a   Calabresi, Peter A ^a   Newsome, Scott D ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRENTUXIMAB VEDOTIN; CORTICOSTEROID; EFALIZUMAB; MONOCLONAL ANTIBODY; NATALIZUMAB; RITUXIMAB; ANTIBODY; ANTIBODY CONJUGATE; CAC10 VCMMAE; CAC10-VCMMAE; CD31 ANTIGEN; IMMUNOLOGIC FACTOR;

BRAIN BIOPSY; CELL FUNCTION; CELL INFILTRATION; FOOD AND DRUG ADMINISTRATION; HOSPICE CARE; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; JC VIRUS; MULTIPLE SCLEROSIS; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROTEIN BINDING; TREATMENT DURATION; ADULT; ARTICLE; CASE REPORT; CUTANEOUS T CELL LYMPHOMA; FEMALE; IMMUNOLOGY; LEUKOENCEPHALOPATHY; TREATMENT OUTCOME;

ADULT; ANTIBODIES; ANTIGENS, CD31; FEMALE; HUMANS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOCONJUGATES; IMMUNOLOGIC FACTORS; LEUKOENCEPHALOPATHIES; LYMPHOMA, T-CELL, CUTANEOUS; MAGNETIC RESONANCE IMAGING; TREATMENT OUTCOME;

EID: 84871186228     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3182749f17     Document Type: Article

References (6)

1. Clifford DB, DeLuca A, Simpson DM, Arendt G, Giovannoni G, Nath A. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 2010;9:438-446.
2. Major EO. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med 2010;61:35-47.
3. Carson KR, Focosi D, Major EO, et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol 2009; 10:816-824.
4. Fanale MA, Forero-Torres A, Rosenblatt JD, et al. A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies. Clin Cancer Res 2012;18:248-255.
5. Tan IL, McArthur JC, Clifford DB, Major EO, Nath A. Immune reconstitution inflammatory syndrome in natalizumab-associated PML. Neurology 2011;77:1061-1067.
6. Harrison DM, Newsome SD, Skolasky RL, McArthur JC, Nath A. Immune reconstitution is not a prognostic factor in progressive multifocal leukoencephalopathy. J Neuroimmunol 2011;238:81-86.